menu search

MNKTQ / Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the American College of Gastroenterology (ACG) Annual Scientific Meeting

Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the American College of Gastroenterology (ACG) Annual Scientific Meeting
– Findings from two clinical studies and one health economic database analysis provide insight into HRS treatment outcomes with TERLIVAZ,1 patients' cardiac health2 and association between hospital size and overall outcomes for chronic liver disease patients3 – DUBLIN , Oct. 22, 2023 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKTQ), a global specialty pharmaceutical company, today announced that three posters detailing findings from Mallinckrodt's latest clinical and health economics outcomes research with TERLIVAZ® (terlipressin) for injection for adult patients with hepatorenal syndrome (HRS) with rapid reduction in kidney function1,2,3,4 will be presented at the American College of Gastroenterology (ACG) Annual Scientific Meeting in Vancouver, British Columbia, taking place October 20-25, 2023. TERLIVAZ is the first and only FDA-approved product indicated to improve kidney function in adults with HRS with rapid reduction in kidney function,4 an acute and life-threatening condition requiring hospitalization.5 TERLIVAZ is not approved in Canada. Read More
Posted: Oct 22 2023, 15:05
Author Name: PRNewsWire
Views: 031171

MNKTQ News  

Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the American College of Gastroenterology (ACG) Annual Scientific Meeting

By PRNewsWire
October 22, 2023

Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the American College of Gastroenterology (ACG) Annual Scientific Meeting

– Findings from two clinical studies and one health economic database analysis provide insight into HRS treatment outcomes with TERLIVAZ,1 patients' more_horizontal

Mallinckrodt bankruptcy plan gains approval from federal court

By Market Watch
October 10, 2023

Mallinckrodt bankruptcy plan gains approval from federal court

Prescription opioid maker Mallinckrodt MNKTQ on Tuesday gained federal court approval to erase more than $1 billion of payments intended for people wi more_horizontal


Search within

Pages Search Results: